-

Shareholder Alert: Robbins LLP is Investigating the Officers and Directors of Pintec Technology Holdings Limited (PT) on Behalf of Shareholders

SAN DIEGO & BEIJING--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Pintec Technology Holdings Limited (NASDAQ: PT) for potential material misstatements and violations of federal securities laws pursuant to its October 2018 initial public offering ("IPO"). Pintec offered more than $3.7 million American Depository Shares at $11.88 per share and raised $40.7 million in gross proceeds. Pintec's stock has precipitously declined and by August 5, 2019, shares of Pintec closed at only $3.40 per share.

On June 15, 2020, Pintec disclosed that it could not timely file its 2019 annual report, disclosing it had "erroneously recorded revenue earned from certain technical service fee on a net basis" for fiscal 2017 and 2018. Since the IPO, Pintec’s stock has traded as low as $0.92 per share, significantly below the $11.88 offering price.

If you purchased shares of Pintec stock in its October 2018 IPO at $11.88 per share, click here.

Pintec Technology Holdings Limited (PT) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
LKandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Pintec settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:PT
Release Versions
English
$Cashtags
$PT
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Leo Kandinov
Robbins LLP
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom